Assessing The Risk Of Febrile Neutropenia For Myelosuppressive Chemotherapy In Patients Who Are Receiving Pegfilgrastim On Body Injector As A Prophylaxis Treatment In Real World Setting
Latest Information Update: 25 Jan 2021
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Chemotherapy induced febrile neutropenia
- Focus Therapeutic Use
Most Recent Events
- 11 Dec 2020 Interim results (n=1930) presented at the 43rd Annual San Antonio Breast Cancer Symposium
- 17 Jan 2020 New trial record
- 14 Dec 2019 As of 25 June 2019, N=1,048 patients have been enrolled and Two interim analyses will be conducted after 1,000 and 2,000 patients have been enrolled and received study treatment as per at the 42nd Annual San Antonio Breast Cancer Symposium.